Company Filing History:
1 out of 3 
1 out of 1,099 
1 out of 1 Years Active: 2025
Title: The Innovations of Feng Cheng
Introduction
Feng Cheng is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of biocatalysis, particularly in the preparation of pharmaceutical intermediates. His work has led to advancements that enhance the efficiency and effectiveness of drug production.
Latest Patents
Feng Cheng holds a patent for a transaminase mutant and its application in the preparation of sitagliptin intermediates. The patent describes a transaminase mutant obtained through specific amino acid substitutions, which include the replacement of tyrosine with proline at position 74, glutamic acid with aspartic acid at position 228, leucine with alanine at position 254, and methionine with threonine at position 290 of the amino acid sequence shown in SEQ ID NO: 2. This invention utilizes wet cells or a purified transaminase as a biocatalyst, along with a sitagliptin precursor ketone or a prochiral carbonyl compound as a substrate. The method achieves a total yield of approximately 82%, with an enantiomeric excess (e.e.) value of the product reaching 99%.
Career Highlights
Feng Cheng has worked with Zhejiang Yongtai Technology Co., Ltd. and Zhejiang University, where he has applied his expertise in biocatalysis and pharmaceutical development. His innovative approaches have contributed to the advancement of drug manufacturing processes.
Collaborations
Feng Cheng has collaborated with notable colleagues, including Zhiqiang Liu and Xiaojian Zhang. Their combined efforts have furthered research and development in the field of biocatalysis.
Conclusion
Feng Cheng's contributions to the field of biocatalysis and his innovative patent for a transaminase mutant highlight his role as a significant inventor in pharmaceutical development. His work continues to influence the efficiency of drug production processes.